Log In
Print
BCIQ
Print
Print this Print this
 

SER-109

  Manage Alerts
Collapse Summary General Information
Company Seres Therapeutics Inc.
DescriptionOral mixture of microbiome organisms
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic
Latest Stage of DevelopmentPhase II
Standard IndicationClostridium
Indication DetailsPrevent recurrent Clostridium difficile infection (CDI); Treat recurrent Clostridium difficile infection (CDI)
Regulatory Designation U.S. - Breakthrough Therapy (Prevent recurrent Clostridium difficile infection (CDI))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today